Patrick Campbell

Discussing the combined and respective roles of nutrition and pharmacological agents in the management of obesity.

New research from an analysis of the Rush MAP is examining associations between FGCRS and cognitive decline later in life.

A new analysis from SCAI 2020 is shedding light on the use of the Melody TPV in patients who underwent valve implantation within an existing dysfunctional right ventricular outflow tract conduit or bioprosthetic pulmonary valve.

A new analysis of 28 studies including more than 90k patients suggests 1-in-10 of these conditions is misdiagnosed, results in delays in treatment and potential harm.

Data presented at SCAI 2020 examining a novel cell therapy suggests it could help reduce angina in patients with non-obstructive coronary artery disease.

An analysis of the TWILIGHT trial presented at SCAI examines SYNERGY BP-EES in a high-risk patient population.

Results of the latest REDUCE-IT analysis shed light on the degree to which icosapent ethyl can reduce revascularization.

New research suggests the presence of either condition can wreak havoc on an older adult's ability for movement, self-care, and household activities.

New research has found use of medication alone was noninferior to using medication and graduated compression socks for preventing VTE following non-emergency surgery.

New research suggests there may be a link between elevated fasting blood glucose levels and cognitive decline after a stroke.

New research suggests consuming just one sugar-sweetened beverage per day increases risk of CVD by nearly 20% in women.

New research suggests a residual shunt following PFO closure puts patients at a much greater risk of recurrent stroke or TIA.

A new AI model from the New York Eye and Ear Infirmary of Mount Sinai boasts 99.2% accuracy for diagnosing intermediate or late AMD.

A new research letter has found declines in rural areas have not been as pronounced as declines in metropolitan areas.

New research suggests a group of 6 cancer biomarkers was associated with all-cause mortality and HF hospitalizations.

A discussion on unanswered questions and concerns among clinicians related to sickle cell disease and the ongoing COVID-19 pandemic.

The latest scientific statement from the association highlights the importance of healthy diet at a young age on preventing CVD later in life.

Discussing the results of a study examining impact of vitamin D and homotaurine supplementation on early to intermediate age-related macular degeneration.

Rishi Singh, MD, discusses differences in disease activity noted among nAMD patients enrolled in the pivotal HAWK and HARRIER trials.

Discussing what data from fellow eyes of a 3-year study tell us about disease course of non-infectious uveitis of the posterior segment with an assistant professor from the Cole Eye Institute.

A Q&A with the medical director of clinical ophthalmology with Genentech about the humanized monoclonal antibody in treatment of NMOSD.

Discussing the impact of high-intensity statin therapy on patients with dry AMD with a study investigator from Byers Eye Institute.

Daniel Kiernan, MD, discusses the results of a study examining dexamethasone intracameral drug-delivery suspension compared with topical corticosteroids for inflammation following vitreoretinal surgery.

Discussing the latest data from Adverum Biotechnologies related to ADVM-022 and the ongoing phase 1 OPTIC trial with the trial's principal investigator.

Research from ARVO 2020 suggest a 4-minute educational video could more than double compliance with patching in pediatric patients with ambylopia.

Discussing how end of study results from the phase 2 LADDER trial inform clinicians on the use of PDS with ranibizumab.

New data from Mount Sinai Hospital suggests anticoagulant use could improve survival rates among patients hospitalized with COVID-19.

New research suggests the prevalence of depression and anxiety is greater among patients with diabetic retinopathy.

After receiving approval for a similar indication in type 2 diabetics in late 2019, the FDA has approved dapagliflozin for reducing risk of CV death and hospitalization in patients with HFrEF.

A new analysis of STAIRWAY from ARVO 2020 is shedding additional light on the effects of faricimab use.